{"id":"NCT01435655","sponsor":"Pfizer","briefTitle":"The Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M Transthyretin","officialTitle":"The Effect On Transthyretin Stabilization, Safety, Tolerablity, Efficacy And Pharmacokinetics Of Orally Administered Tafamidis In Transthyretin Amyloid Polyneuropathy Patients With V30m Or Non-v30m Transthyretin: A Phase Iii, Open-label Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-11","primaryCompletion":"2014-02","completion":"2014-02","firstPosted":"2011-09-16","resultsPosted":"2015-09-09","lastUpdate":"2015-09-09"},"enrollment":10,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Transthyretin Familial Amyloid Polyneuropathy"],"interventions":[{"type":"DRUG","name":"tafamidis","otherNames":["tafamidis meglumine"]}],"arms":[{"label":"open","type":"EXPERIMENTAL"}],"summary":"Tafamidis has been developed as an oral specific stabilizer of transthyretin tetramer.","primaryOutcome":{"measure":"Number of Participants With Transthyretin (TTR) Stabilization at Week 8 Compared With Baseline as Measured by a Validated Immunoturbidimetric Assay","timeFrame":"8 weeks","effectByArm":[{"arm":"Tafamidis 20 mg","deltaMin":10,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":2,"countries":["Japan"]},"refs":{"pmids":["31353964"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3461010&StudyName=The%20Effect%20Of%20Tafamidis%20For%20The%20Transthyretin%20Amyloid%20Polyneuropathy%20Patients%20With%20V30M%20Or%20Non-V30M%20Transthyretin"]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":10},"commonTop":["Nasopharyngitis","Muscular weakness","Thermal burn","Cataract","Vitreous opacities"]}}